Published in final edited form as:
Chem Res Toxicol. 2014 January 21; 27(1): 27–33. doi:10.1021/tx400305w.

Metabolism of styrene to styrene oxide and vinylphenols in cytochrome P450 2F2- and P450 2E1-knockout mouse liver and lung microsomes

Shuijie Shen[1], **Lei Li**[2], **Xinxin Ding**[2], and **Jiang Zheng**[1,3,4]

[1]Center for Developmental Therapeutics, Seattle Children's Research Institute, Seattle, Washington 98101

[2]Wadsworth Center, New York State Department of Health, and School of Public Health, State University of New York at Albany, Albany, New York 12201

[3]Division of Gastroenterology and Hepatology, Department of Pediatrics, University of Washington, Seattle, Washington 98105

[4]Shenyang Pharmaceutical University, Shenyang, 110016, P. R. China

Abstract

Pulmonary toxicity of styrene is initiated by cytochromes P450-dependent metabolic activation. P450 2E1 and P450 2F2 are considered to be two main cytochrome P450 (CYP) enzymes responsible for styrene metabolism in mice. The objective of the current study was to determine the correlation between the formation of styrene metabolites (i.e. styrene oxide and 4-vinylphenol) and pulmonary toxicity of styrene, using *Cyp2e1*- and *Cyp2f2*-null mouse models. Dramatic decrease in the formation of styrene glycol and 4-vinylphenol was found in *Cyp2f2*-null mouse lung microsomes, relative to that in the wild-type mouse lung microsomes. However, no significant difference in the production of the styrene metabolites was observed between lung microsomes obtained from *Cyp2e1*-null and the wild-type mice. The knock–out and wild-type mice were treated with styrene (6.0 mmol/kg, ip), and cell counts and LDH activity in bronchoalveolar lavage fluids were monitored to evaluate the pulmonary toxicity induced by styrene. *Cyp2e1*-null mice displayed similar susceptibility to lung toxicity of styrene as the wild-type animals. However, *Cyp2f2*-null mice were resistant to styrene-induced pulmonary toxicity. In conclusion, both P450 2E1 and P450 2F2 are responsible for the metabolic activation of styrene. The latter enzyme plays an important role in styrene-induced pulmonary toxicity. Both styrene oxide and 4-vinylphenol are suggested to participate in the development of lung injury induced by styrene.

Keywords

Styrene; reactive metabolites; P450 2E1; P450 2F2

Corresponding Author: Jiang Zheng, PhD, Center for Developmental Therapeutics, Seattle Children's Research Institute, Seattle, Washington 98101, Division of Gastroenterology and Hepatology, Department of Pediatrics, University of Washington, Seattle, Washington 98105, Shenyang Pharmaceutical University, Shenyang, 110016, P. R. China, jiang.zheng@seattlechildrens.org, Tel: 206-884-7651, Fax: 206-987-7660.

Introduction

Styrene (**1**) is an important industrial chemical widely used in the manufacture of plastics, resins, and synthetic rubbers.[1] Styrene has been detected in cigarette smoke, engine exhausts, heating systems, newly installed carpets, painting,[2] and even food and drinking water stored in polystyrene containers.[3,4] The highest levels of human exposure to styrene occur in the reinforced plastic industry.[5–7] Occupational and environmental exposures to styrene take place mainly by inhalation. Styrene is both hepatotoxic and pneumotoxic in rodents and it is classified as a possible carcinogen (IIB) in humans.[8–10] The National Toxicity Program lists styrene as reasonably anticipated human carcinogen.[11]

Metabolic activation is considered to be a critical step for styrene-induced pulmonary toxicity.[12] The main pathway to metabolize styrene is the epoxidation of the vinyl group to styrene-7,8-oxide (styrene oxide, SO, **2**, Scheme 1) catalyzed by cytochromes P450. The resulting styrene oxide is further hydrated to styrene glycol (SG, **3**) or conjugated with glutathione to glutathione conjugates.[13,14] Styrene oxide is both mutagenic and carcinogenic.[13,15] It is thought to be one of the major toxic styrene metabolites. Aromatic hydroxylation is another metabolism pathway of styrene, which leads to the formation of 2-vinylphenol (2-VP, **4**), 3-vinylphenol (3-VP, **5**), and 4-vinylphenol (4-VP, **6**) (Scheme 1). Metabolic hydroxylation of styrene to 4-VP has been well studied *in vitro* and *in vivo*.[6,16–18] Recently, Linhart et al. and our group characterized 2-VP and 3-VP as styrene metabolites in mice.[19,20] We found 2-VP was the major isomer among the VP metabolites detected in mouse liver and lung microsomes. 4-VP has been reported more toxic than SO,[21,22] and our earlier study also showed that 4-VP was more toxic than 2-VP and 3-VP in mice.[19] The VPs were further metabolized to the corresponding hydroxystyrene oxides, vinylcatechols, and/or vinylhydroquinone in mouse microsomes,[19] but whether these metabolites cause cytotoxicity remains unclear.

P450 2F2 and P450 2E1 are considered as the major cytochrome P450 (CYP) enzymes responsible for styrene metabolism in mice, although other P450 proteins may be partially involved, such as P450 2B.[13,23–25] P450 2E1 is suggested to dominate the metabolism of styrene in mouse liver, due to its abundant expression,[26,27] while P450 2F2 seems solely to take effect in mouse lung, since P450 2F2 is mainly expressed in mouse lung terminal bronchioles and nasal olfactory epithelium.[25,28] Recent reports emphasized that mouse P450 2F2 is important in the unique toxicity of mouse lung to several lung toxicants.[29]

Transgenic animals have been applied to investigate the metabolism and toxicity of styrene. Carlson found a significant decrease in the metabolism of styrene to styrene oxide in *Cyp2e1*-null mouse liver microsomes but not in the lung microsomes.[23] In addition, *Cyp2e1*-null mice were less susceptible to the hepatotoxicity of styrene than the wild-type animals. However, little change in the susceptibility to the pulmonary toxicity of styrene was observed in *Cyp2e1*-null mice in comparison with that of the wild-type mice.[30] The objectives of the present study included the investigation of the roles of P450 2E1 and P450 2F2 in metabolic transformation of styrene to styrene oxide and vinyl phenols in mouse liver and lung microsomes, using *Cyp2e1*-null and *Cyp2f2*-null mouse models. This allows us to

better understand the relationship between styrene-induced toxicity and its metabolites styrene oxide and vinyl phenols.

Materials and methods

Chemicals and Apparatus

Styrene (>99%), β-nicotinamide adenine dinucleotide 2′-phosphate reduced tetrasodium salt (NADPH), *N*,*O*-bis(trimethylsilyl)-trifluoroacetamide (BSTFA), and 4-VP were purchased from Sigma-Aldrich (St. Louis, MO). Other chemicals were of analytical grade or higher. Styrene glycol-d_8 (SG-d_8), 2-VP, and 3-VP were synthesized in our lab.[19] An HP 5890 Series II gas chromatograph with a capillary GC column (J&W Scientific BD-5MS, 20 m × 0.18 mm id, film thickness 0.18 μm), an HP 5971A mass-selective detector (MSD), and an HP 7673 autosampler was used to analyze metabolite samples. HP Chemstation B.02.05 software was used for GC/MS control and data collection.

Animals

Cyp2e1-null mice (129/Sv-*Cyp2e1tm1Gonz*/J) and the wild-type control mice (129S1/SvImJ) were purchased from the Jackson Laboratory (Sacramento, CA). The *Cyp2f2*-null mice were developed by Dr. Xinxin Ding's group in Wadsworth Center, New York State Department of Public Health (Albany, New York). The wild-type control mice of *Cyp2f2*-null mice (C57BL/6J) were purchased from the Jackson Laboratory. The animals were housed in an air conditioned room set to maintain 20 – 24 °C, 40 – 60% relative humidity, and 12-h light/dark cycle. The mice were fed standard rodent diets and drinking water *ad libitum*. The mice were bred in the Animal Laboratory of Seattle Children's Research Institute. Only male mice 2 to 3 month old were used to prepare microsomes. Liver and lung microsomes were prepared with the same protocol used in our previous work.[19]

Assessment of P450 2E1 and P450 2F2 expressions

Western blot analysis was carried out to assess the expressions of P450 2E1 and P450 2F2. Protein concentrations of microsomes were measured using bicinchoninic acid protein kit (Pierce Chemical, Rockford, IL). Microsomal proteins (5 μg for liver and 15 μg for lung) were loaded and resolved on SDS-PAGE gel and transferred onto nitrocellulose membranes. The P450 2E1 and P450 2F2 protein bands were probed with rabbit anti-rat P450 2E1 antibody (StressGen, Victoria, BC, Canada) and rabbit anti-P450 2F antibody (custom-prepared by GenScript, Piscataway, NJ). Calnexin, a marker protein for the endoplasmic reticulum, was detected using a rabbit anti-human calnexin antibody (GenScript). The detected bands were captured with a Bio-Rad GS-710 Imaging Densitometer (Bio-Rad, Hercules, CA).

Determination of 4-nitrophenol hydroxylation activity

4-Nitrophenol was used as a substrate to assess P450 2E1 and P450 2F2 activities.[31,32] The incubation mixture contained 1.0 mg protein/mL (mouse liver microsomes) or 0.5 mg protein/mL (lung microsomes), 5.0 mM $MgCl_2$, 1.0 mM NADPH, 500 μM 4-nitrophenol, and 100 mM phosphate buffer (pH 7.4) with a total volume of 0.2 mL. 4-Nitrophenol was added to initiate the microsomal reactions. After incubation for 20 min at 37 °C, 20 μL of 3

M trichloroacetic acid solution was added, followed by vortexing for 1 min. The precipitated proteins were removed by centrifuging at 12,000 rpm for 10 min. Twenty microliters of the resulting supernatant was injected to HPLC for analysis. An Agilent 1100 HPLC system was used to quantify the formation of 4-nitrocatechol. The mobile phase was a mixture of acetonitrile (0.1% trifluoroacetic acid) and water (0.1% trifluoroacetic acid) (2:8, v/v), and the column for separation was Agilent ZORBAX Eclipse XDB C8 (150 × 4.6 mm, 5μm). UV signals were recorded at 245 nm for 4-nitrocatechol. A 4-nitrocatechol standard curve was prepared with a series of 4-nitrocatechol solutions at concentrations of 2.0, 5.0, 10, 20, and 50 μM in 100 mM phosphate buffer. 4-Nitrocatechol concentrations were calculated by external standard curve method.

Incubations of styrene in mouse liver and lung microsomes

Microsomal incubations were carried out in glass tubes with PTFE-faced rubber-lined screw caps (10 × 1.3 cm id, Kimble Chase, Vineland, NJ). The incubation mixtures contained mouse liver or lung microsomes (1.0 mg protein/mL), 5.0 mM $MgCl_2$, 2.0 mM NADPH, 500 μM styrene, in 100 mM phosphate buffer (pH 7.4) with a total volume of 0.5 mL. After preincubation in a 37 °C water bath shaker for 2 min, reactions were initiated by adding of 5.0 μL of styrene stock solution (50 mM in acetonitrile), and the incubation tubes were immediately sealed with caps. Incubations lacking with NADPH were treated as blank controls.

After incubation for 20 min, the reactions were terminated by adding 3 mL of ice-cold ethyl acetate, followed by addition of 5.0 μL of internal standard solution containing SG-d_8 (0.1 mM in acetonitrile). The mixture was vortexed for 2 min and centrifuged at 4,000 rpm for 10 min. The organic supernatant was transferred to a clean test tube and dried under nitrogen gas flow. The residue was reconstituted with 50 μL of 20% BSTFA-acetonitrile solution (v/v), vortexed, incubated at 60 °C for 30 min, and subject to GC/MS analysis.

Determination of kinetics of styrene metabolism in liver and lung microsomes

To determine the kinetic parameters of styrene metabolism in various types of microsomes, styrene at 1.0, 2.0, 5.0, 10, 20, 60, or 100 μM was incubated in microsomes. The incubation mixtures contained mouse liver or lung microsomes (1.0 mg protein/mL), 5.0 mM $MgCl_2$, 1.0 mM NADPH, and 100 mM phosphate buffer (pH 7.4) with a total volume of 0.5 mL. The reactions were initiated by addition of styrene. After incubation at 37 °C for 5 min, the reactions were stopped by adding of 3 mL ice-cold ethyl acetate. After adding internal standard SG-d_8 (5.0 μL, 0.1 mM), the samples were processed and derivatized as described previously. The resulting derivatized SG in the samples was analyzed by GC/MS. V_{max} and K_m values were calculated by non-linear least-squares regression analysis using SigmaPlot software.

Determination of pulmonary toxicity of styrene in mice

Male *Cyp2e1*-null, *Cyp2f2*-null, and the corresponding wild-type mice (20 – 26 g) were divided into control and dose groups (6 mice each). The dose groups were treated with styrene (6.0 mmol/kg, i.p.) dissolved in vegetable oil, and the control groups were given vegetable oil (5.0 mL/kg) intraperitoneally. After 18 h, the mice were terminated by CO_2

asphyxiation. The trachea was exposed, where a small nick was made, and an oral feeding needle was inserted and tied in place. The lungs were lavaged twice with 0.9 mL of room-temperature PBS (Mediatech Inc., Manassas, VA). The bronchoalveolar lavage fluid (BALF) was collected (about 1.6 mL) and placed on ice. Cells in BALF were counted using a hemocytometer under a microscope. The remaining BALF from each mouse was centrifuged at 3,000 rpm for 5 min. The lactate dehydrogenase (LDH) activity in the BALF supernatant was measured by an In Vitro Toxicology Assay Kit, LDH based (Sigma-Aldrich, MO).

GC/MS analysis

The column temperature was held at initial temperature 60 °C for 1 min after injection (splitless) of 1 μL sample, followed by an increase to 170 °C at 10 °C/min, then increased at 20 °C/min to 250 °C and held for 2 min. Injector port temperature was 250 °C, and detector temperature was 280 °C. GC column was J&W Scientific BD-5MS (20 m × 0.18 mm id; film thickness: 0.18 μm). Carrier gas was helium with column head pressure set at 10 psi at 50 °C. Dwell time was 50 ms, and EI ionization voltage was 70 eV. Styrene metabolites were derived with BSTFA in 20% BSTFA acetonitrile solution at 60 °C for 30 min. Target ions of the derived styrene metabolites were monitored in SIM mode (*m/z* 177 and 192 for VP-TMS; *m/z* 179 for SG-TMS; *m/z* 185 for SG-d_8-TMS).

Determination of VP and SG contents was achieved using the corresponding standard curves (VPs: 5.0 nM - 500 nM and SG: 2.0 - 200 μM). Standard curves were fitted with linear equation, where × was the concentration of analytes and y was the peak ratio of analytes *vs.* internal standard. The correlation coefficient of the standard curves $r^2 > 0.998$.

Data analysis

All values were represented as mean ± SD. Two-sided, unpaired student *t*-test was used to compare the difference between the wild-type and knockout mouse microsomes. The styrene metabolism kinetic parameters were fitted with enzyme kinetic equation with Sigmaplot 9.0 software (Systat Software, CA).

Results

P450 2E1 and P450 2F2 protein expressions

As an initial step, we determined the expressions of P450 2E1 and P450 2F2 in the liver and lung of the knock-out and wild-type mice. The P450 proteins were assessed by immunoblot, using the corresponding antibodies. As expected, little P450 2E1 protein was found in *Cyp2e1*-null mouse liver as well as in the lung (Figure 1). In addition, the immunoblot results demonstrated that much more P450 2E1 protein was expressed in the liver than in the lung in the wild type mice (Figure 1). P450 2F2 protein was detected in the wild-type mouse liver and lung but not in those tissues obtained from *Cyp2f2*-null mice (Figure 2). Apparently, similar levels of P450 2F2 expression were found in the lung as in the liver of the wild-type mice (Figures 1 and 2).

Microsomal 4-nitrophenol hydroxylation activity

Besides the assessment of P450 2E1 and P450 2F2 protein expressions, we compared their activities in liver and lung microsomes obtained from *Cyp2f2*-null, *Cyp2e1*-null mice and the corresponding wild-type mice. The enzyme activities were measured by assessing hydroxylation of 4-nitrophenol. As shown in Table 1, a significant decrease in 4-nitrophenol hydroxylation activity was observed in both *Cyp2f2*-null and *Cyp2e1*-null mouse liver and lung microsomes, relative to those obtained from the corresponding wild-type animals. Interestingly, the loss of 4-nitrophenol hydroxylation activity took place mainly in the liver of *Cyp2e1*-null mice (46.8 % in liver vs. 25.2% in lung), while the enzyme activity loss almost exclusively occurred in the lung of *Cyp2f2*-null mice (86.0% in lung vs. 15.1% in liver), compared with those of the corresponding wild-type mice (Table 1).

Metabolism of styrene in *Cyp2e1*-null and wild-type mouse liver and lung microsomes

To understand the role of P450 2E1 in styrene metabolism, we investigated the biotransformation of styrene to styrene glycol (SG) and vinyl phenols (VPs) in liver and lung microsomes of *Cyp2e1*-null and the wild-type mice. The rates of SG and VP production are listed in Table 2 (the unit for SG formation: nmol/min/mg protein; the unit for VP production: pmol/min/mg protein). As expected, styrene was mainly metabolized to SG in all four types of microsomes. The formation of SG was significantly slowed down (44.2% drop) in *Cyp2e1*-null mouse liver microsomes, compared with the reactions taking place in the wild-type liver microsomes. However, no significant difference in the rate of SG production was observed between the lung microsomes obtained from *Cyp2e1*-null and the wild-type mice. All three vinyl phenols were detected in *Cyp2e1*-null and wild-type mouse liver and lung microsomes at low rates, in comparison with that of SG formation. The order of VP formation was 2-VP > 4-VP > 3-VP in wild-type mouse liver and lung microsomes. Similar order of the VP production was found in the *Cyp2e1*-null microsomes but at lower rates, relative to that observed in the wild-type mouse liver and lung microsomes. Interestingly, lung microsomes generated more 2-VP than liver microsomes of both *Cyp2e1*-null and the wild-type mice.

Metabolism of styrene in *Cyp2f2*-null and wild-type mouse liver and lung microsomes

The role of P450 2F2 in styrene metabolism was also studied, using *Cyp2f2*-null and wild-type mouse liver and lung microsomes. A dramatic decrease in the rate of SG generation was observed in *Cyp2f2*-null mouse liver and lung microsomes, compared with that found in wild-type mouse liver and lung microsomes. Specifically, as much as 64% drop in the formation of SG from styrene was found in *Cyp2f2*-null mouse lung microsomes, and 25% drop in liver microsomes, relative to that observed in wild-type mouse lung or liver microsomes (Table 3). The three VPs were all found in wild-type mouse liver and lung microsomes. However, only 2-VP was observed in *Cyp2f2*-null mouse liver microsomes, and little VPs detected in *Cyp2f2*-null mouse lung microsomes after incubation with styrene.

Kinetics of styrene metabolism in *Cyp2e1*-null, *Cyp2f2*-null, and wild-type mouse liver and lung microsomes

The kinetic parameters of vinyl epoxidation of styrene in *Cyp2e1*-null, *Cyp2f2*-null, and the corresponding wild-type mouse liver and lung microsomes were determined by incubation of styrene at a serial of concentrations in the individual microsomes. V_{max} and K_m values were calculated based on the production of the resulting SG. No statistical difference in V_{max} and K_m values was observed in both liver microsomal or lung microsomes between *Cyp2e1*-null mice and the wild-type animals (Table 4). However, reduced V_{max} values were observed in liver and lung microsomes of *Cyp2f2*-null mice (30% and 63% decreases in liver and lung microsomes, respectively), relative to those of the wild-type animals. Interestingly, decreased K_m values were also observed in the two types of microsomes (47% and 53% decreases in liver and lung microsomes, respectively). As a result, there is no difference in V_{max}/K_m values between the microsomes obtained from *Cyp2f2*-null and the wild-type mice (Table 4).

Acute pulmonary toxicity of styrene in *Cyp2e1*-null, *Cyp2f2*-null and the wild-type mice

Pulmonary toxicity of styrene was evaluated by monitoring cell counts and LDH activity in bronchoalveolar lavage fluids (BALF). Treatment of styrene induced a significant elevation in BALF cell counts and LDH activity in both *Cyp2e1*-null and the wild-type mice, and *Cyp2e1*-null mice were as susceptible to lung toxicity of styrene as the wild-type animals. In contrast, no changes in cell counts and LDH activity in BALF were observed in *Cyp2f2*-null mice after treatment with styrene, and the knock-out animals were not susceptible to the styrene toxicity. However, increased BALF cell counts and LDH activity were observed in the corresponding wild-type mice given the same dose of styrene (Table 5).

Discussion

Multiple cytochromes P450 are involved in styrene metabolism,[13,14] among which P450 2E1 and P450 2F2 have been reported to be the major P450 enzymes responsible for styrene metabolism in mice.[23] It has been suggested that P450 2E1 is more important to styrene metabolism in liver, while P450 2F2 plays the dominant role in styrene metabolism in mouse lung, presumably due to the abundance of the individual enzymes expressed in the respective organs.[25,29,33] However, our present immunoblot data did not support the presumption. The expression of P450 2F2 in the liver is at least as much as in the lung in 129S1/SvImJ and C57BL/6J mice (Figures 1 and 2). In the present study, we investigated the sole role of P450s 2E1 and 2F2 in metabolic activation of styrene by use of *Cyp2e1*-null and *Cyp2f2*-null mouse models in comparison with the corresponding wild-type mice.

Vinyl epoxidation of styrene has been suggested to be a key reaction to trigger the toxicity of styrene. We examined the rate of styrene epoxidation in liver and lung microsomes obtained from *Cyp2e1*-null and the wild-type mice. The production of styrene glycol (SG), the hydrated product of styrene oxide, was slowed down by 50% in *Cyp2e1*-null mouse liver microsomes, compared with that in liver microsomes of the wild-type mice. However, lung microsomes of *Cyp2e1*-null mice showed the similar activity as that of the wild-type animals. This indicates that lung microsomes of *Cyp2e1*-null mice retained the ability to

metabolize styrene to styrene oxide and that the activity to bioactivate styrene left in the lung microsomes of *Cyp2e1*-null mice was contributed by other P450 enzymes. Clearly, P450 2E1 was not critical for the oxidation of styrene in mouse lung, although it does have the activity for metabolic activation of styrene. The present study showed much lower P450 2E1 content in lung microsomes than that in liver microsomes of the wild-type mice. Carlson reported that *Cyp2e1*-null mice were as susceptible to pulmonary toxicity of styrene as the wild-type animals.[30] Our present study showed that treatment of styrene induced similar magnitude of elevated cell counts and LDH activity in BALF in *Cyp2e1*-null and the wild-type mice after exposure to styrene (Table 7). The similarity in susceptibility to pulmonary toxicity of styrene observed in *Cyp2e1*-null mice and the wild-type mice may result from the observed no change in the formation of styrene oxide in the lungs of the two types of mice given styrene.

In contrast, *Cyp2f2*-null mouse liver microsomes retained 75% activity to oxidize styrene to styrene oxide, compared with the wild-type mouse liver microsomes. This indicates P450 2F2 was not critical in bioactivation of styrene in mouse liver. It is likely that expression of P450 2F2 is limited in mouse liver, relative to the expression of P450 2E1 and that the loss of P450 2F2 did not have significant impact on the microsomal activity for the production of styrene oxide. However, *Cyp2f2*-null mouse lung microsomes showed only one third of the enzyme activity to produce styrene oxide from styrene in comparison with what the wild-type mouse lung microsomes revealed. This implicates that expression of P450 2F2 was essential in vinyl epoxidation of styrene in mouse lung. This situation is very similar to the activity for the hydroxylation of 4- nitrophenol in these microsomes. Dramatically decreased activity for 4-nitrophenol hydroxylation was found in *Cyp2f2*-null mouse lung microsomes, but only a minor decrease in 4-nitrophenol hydroxylation activity observed in the liver microsomes.

Cruzan et al. reported that *Cyp2f2*-null mice were less susceptible to pulmonary toxicity of styrene than the wild-type animals.[34] Our present study showed that treatment with the same dose of styrene did not cause the elevation in cell counts and LDH activity in BALF of *Cyp2f2*-null mice. The observed resistance of *Cyp2f2*-null mice to lung toxicity of styrene may be explained by the loss of enzyme activity for the production of styrene oxide in the lung of *Cyp2f2*-null mice.

Vinyl phenols (VPs) are another group of styrene metabolites, resulting from aromatic hydroxylation of styrene. We examined the production of the VPs in *Cyp2e1*- and *Cyp2f2*-null, and the corresponding wild-type mouse microsomes. As expected, all three VPs, including 2-, 3- and 4-VPs, were found in wild-type mouse liver and lung microsomes. However, significant decreases in the formation of 2-VP and 4-VP were observed in *Cyp2e1*-null mouse liver microsomes, but no or mild decrease in the formation of the VPs was observed in *Cyp2e1*-null mouse lung microsomes. This indicates that P450 2E1 plays an important role in aromatic hydroxylation of styrene in the liver but not in the lung. Dramatic decrease in the production of the VPs was found in *Cyp2f2*-null mouse microsomes. Only 2-VP was found in liver microsomes, and no VPs were detected in lung microsomes. This implies that P450 2F2 is a critical enzyme responsible for metabolism of styrene to the VPs, particularly in the lung.

4-VP has been suggested to be the critical toxic metabolite responsible for styreneinduced pulmonary toxicity.[21,35] However, the results of our present study do not necessarily support this hypothesis. Apparently, the alternations of the levels of 4-VP formed in lung microsomes were consistent with the changes in the susceptibility of mice to the pulmonary toxicity of styrene. However, the changes in the levels of styrene oxide produced in lung microsomal reactions were also consistent with the alternations of the susceptibility of the animals to lung toxicity induced by styrene. Therefore, we cannot exclude the role of styrene oxide in styrene-induced pulmonary toxicity.

Remarkable decreases in V_{max} of styrene vinyl epoxidation were observed in liver and lung microsomes of both *Cyp2e1*-null and *Cyp2f2*-null mice. Meanwhile, the Km value of styrene to the microsomes decreased in these microsomes, accordingly. The reason for the decrease in Km value is unknown and possibly results from the complexity and multiplicity of microsomal P450 enzyme systems. It is likely that styrene binds to multiple P450s with various catalytic capabilities. Among the P450s, P450 2E1 and P450 2F2 are the major enzymes responsible for the epoxidation of styrene.[23,29,30,34] The observed loss of P450 2E1 or P450 2F2 decreased vinyl epoxidation V_{max} but combined with a decrease in apparent K_m value was possibly due to the high styrene-binding capacities of multiple P450s.

In conclusion, both P450 2E1 and P450 2F2 are greatly involved in metabolism of styrene to styrene oxide and the VPs, but their importance in styrene metabolism can vary in the liver and lung. The loss of P450 2E1 activity to metabolize styrene can be compensated in the lung but not in the liver. In contrast, the loss of P450 2F2 activity for styrene metabolism can be compensated in the liver but not in the lung. The susceptibility of mice to pulmonary toxicity of styrene is associated with the level of P450 2F2 expression but not that of P450 2E1 expression in the lung. It is likely that both styrene oxide and 4-VP are involved in pulmonary toxicity induced by styrene.

Acknowledgments

We are grateful to Dr. George Cruzan at ToxWorks for providing us some *Cyp2f2*-null mice. We would like to thank Mr. Andrew Lowe for his assistance in preparation of this manuscript.

Funding sources

This work was supported by NIH Grant HL080226.

Abbreviations

BALF	bronchoalveolar lavage fluid
BSTFA	*N,O*-bis(trimethylsilyl)-trifluoroacetamide
CYP	cytochrome P450
GC/MS	gas chromatography
LDH	lactate dehydrogenase
NADPH	β-nicotinamide adenine dinucleotide 2′-phosphate reduced tetrasodium salt

SDS-PAGE	sodium dodecyl sulfate polyacrylamide gel electrophoresis
SG	styrene glycol
SO	styrene oxide
TMS	trimethylsilyl
VP	vinylphenol

References

1. Miller RR, Newhook R, Poole A. Styrene production, use, and human exposure. Crit. Rev. Toxicol. 1994; 24(Suppl):S1–S10. [PubMed: 7818766]
2. Hodgson AT, Wooley JD, Daisey JM. Emissions of volatile organic compounds from new carpets measured in a large-scale environmental chamber. Air Waste. 1993; 43:316–324. [PubMed: 8457318]
3. Fleming-Jones ME, Smith RE. Volatile organic compounds in foods: a five year study. J. Agric. Food Chem. 2003; 51:8120–8127. [PubMed: 14690406]
4. Tang W, Hemm I, Eisenbrand G. Estimation of human exposure to styrene and ethylbenzene. Toxicology. 2000; 144:39–50. [PubMed: 10781869]
5. Scott D, Preston R. A critical review of the cytogenetic effects of styrene with an emphasis on human population monitoring: a synopsis. Crit. Rev. Toxicol. 1994; 24(Suppl):S47–S48. [PubMed: 7818771]
6. Leibman KC. Metabolism and toxicity of styrene. Environ. Health Perspect. 1975; 11:115–119. [PubMed: 809262]
7. IARC. IARC monographs on the evaluation of carcinogenic risks to humans: some industrial chemicals: some industrial chemicals. IARC Monogr. Eval. Carcinog. Risks Hum. 1994:233–246. [PubMed: 7869572]
8. IARC. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr. Eval. Carcinog. Risks Hum. 2002:1–556.
9. Bond J. Review of the toxicology of styrene. Crit. Rev. Toxicol. 1989; 19:227–249. [PubMed: 2653733]
10. Brown N, Lamb J, Brown S, Neal B. A review of the developmental and reproductive toxicity of styrene. Regul. Toxicol. Pharmacol. 2000; 32:228–247. [PubMed: 11162717]
11. NTP. Report on Carcinogens. Twelfth Edition. Research Triangle Park, NC: U.S. Department of Health and Human Services: National Toxicology Program; 2011. p. 383
12. McConnell E, Swenberg J. Review of styrene and styrene oxide long-term animal studies. Crit. Rev. Toxicol. 1994; 24(Suppl):S49–S55. [PubMed: 7818772]
13. Vodicka P, Koskinen M, Naccarati A, Oesch-Bartlomowicz B, Vodickova L, Hemminki K, Oesch F. Styrene metabolism, genotoxicity, and potential carcinogenicity. Drug Metab. Rev. 2006; 38:805–853. [PubMed: 17145703]
14. Sumner SJ, Fennell TR. Review of the metabolic fate of styrene. Crit. Rev. Toxicol. 1994; 24(Suppl):S11–S33. [PubMed: 7818768]
15. NTP. Report on Carcinogens. Twelfth Edition. Research Triangle Park, NC: U.S. Department of Health and Human Services: National Toxicology Program; 2011. p. 391
16. Pantarotto C, Fanelli R, Bidoli F, Morazzoni P, Salmona M, Szczawinska K. Arene oxides in styrene metabolism, a new perspective in styrene toxicity? Scand J Work Environ. Health. 1978; 42(Suppl):67–77. [PubMed: 734419]
17. Pfaffli P, Hesso A, Vainio H, Hyvonen M. 4-Vinylphenol excretion suggestive of arene oxide formation in workers occupationally exposed to styrene. Toxicol. Appl. Pharmacol. 1981; 60:85–90. [PubMed: 6792746]

18. Watabe T, Hiratsuka A, Aizawa T, Sawahata T, Ozawa N, Isobe M, Takabatake E. Studies on metabolism and toxicity of styrene. IV. 1-Vinylbenzene 3, 4-oxide, a potent mutagen formed as a possible intermediate in the metabolism in vivo of styrene to 4-vinylphenol. Mutat. Res. 1982; 93:45–55. [PubMed: 7038469]
19. Shen S, Zhang F, Gao L, Zeng S, Zheng J. Detection of phenolic metabolites of styrene in mouse liver and lung microsomal incubations. Drug Metab. Dispos. 2010; 38:1934–1943. [PubMed: 20724499]
20. Linhart I, Mraz J, Scharff J, Krouzelka J, Duskova S, Nohova H, Vodickova L. New urinary metabolites formed from ring-oxidized metabolic intermediates of styrene. Chem. Res. Toxicol. 2010; 23:251–257. [PubMed: 20020750]
21. Carlson GP, Ullman M, Mantick NA, Snyder PW. 4-Vinylphenol-induced pneumotoxicity and hepatotoxicity in mice. Toxicol. Pathol. 2002; 30:565–569. [PubMed: 12371665]
22. Harvilchuck JA, Carlson GP. Comparison of styrene and its metabolites styrene oxide and 4-vinylphenol on cytotoxicity and glutathione depletion in Clara cells of mice and rats. Toxicology. 2006; 227:165–172. [PubMed: 16956708]
23. Carlson G. In vitro metabolism of styrene to styrene oxide in liver and lung of Cyp2E1 knockout mice. J. Toxicol. Environ. Health A. 2003; 66:861–869. [PubMed: 12746132]
24. Zhang F, Lowe ER, Rick DL, Qiu X, Leibold E, Cruzan G, Bartels MJ. In vitro metabolism, glutathione conjugation, and CYP isoform specificity of epoxidation of 4-vinylphenol. Xenobiotica. 2011; 41:6–23. [PubMed: 20925585]
25. Cruzan G, Carlson G, Johnson K, Andrews L, Banton M, Bevan C, Cushman J. Styrene respiratory tract toxicity and mouse lung tumors are mediated by CYP2F-generated metabolites. Regul. Toxicol. Pharmacol. 2002; 35:308–319. [PubMed: 12202046]
26. Choudhary D, Jansson I, Schenkman JB, Sarfarazi M, Stoilov I. Comparative expression profiling of 40 mouse cytochrome P450 genes in embryonic and adult tissues. Arch. Biochem. Biophys. 2003; 414:91–100. [PubMed: 12745259]
27. Choudhary D, Jansson I, Stoilov I, Sarfarazi M, Schenkman JB. Expression patterns of mouse and human CYP orthologs (families 1-4) during development and in different adult tissues. Arch. Biochem. Biophys. 2005; 436:50–61. [PubMed: 15752708]
28. Baldwin RM, Jewell WT, Fanucchi MV, Plopper CG, Buckpitt AR. Comparison of pulmonary/nasal CYP2F expression levels in rodents and rhesus macaque. J. Pharmacol. Exp. Ther. 2004; 309:127–136. [PubMed: 14724224]
29. Cruzan G, Bus J, Banton M, Gingell R, Carlson G. Mouse specific lung tumors from CYP2F2-mediated cytotoxic metabolism: an endpoint/toxic response where data from multiple chemicals converge to support a mode of action. Regul. Toxicol. Pharmacol. 2009; 55:205–218. [PubMed: 19589367]
30. Carlson G. Comparison of the susceptibility of wild-type and CYP2E1 knockout mice to the hepatotoxic and pneumotoxic effects of styrene and styrene oxide. Toxicol. Lett. 2004; 150:335–339. [PubMed: 15110085]
31. Simmonds AC, Ghanayem BI, Sharma A, Reilly CA, Millen B, Yost GS, Forkert PG. Bioactivation of 1,1-dichloroethylene by CYP2E1 and CYP2F2 in murine lung. J. Pharmacol. Exp. Ther. 2004; 310:855–864. [PubMed: 15123768]
32. Forkert PG, Baldwin RM, Millen B, Lash LH, Putt DA, Shultz MA, Collins KS. Pulmonary bioactivation of trichloroethylene to chloral hydrate: relative contributions of CYP2E1, CYP2F, and CYP2B1. Drug Metab. Dispos. 2005; 33:1429–1437. [PubMed: 15987776]
33. Shultz MA, Morin D, Chang AM, Buckpitt A. Metabolic capabilities of CYP2F2 with various pulmonary toxicants and its relative abundance in mouse lung subcompartments. J. Pharmacol. Exp. Ther. 2001; 296:510–519. [PubMed: 11160638]
34. Cruzan G, Bus J, Hotchkiss J, Harkema J, Banton M, Sarang S. CYP2F2-generated metabolites, not styrene oxide, are a key event mediating the mode of action of styrene-induced mouse lung tumors. Regul. Toxicol. Pharmacol. 2012; 62:214–220. [PubMed: 22041433]
35. Cruzan G, Carlson GP, Johnson KA, Andrews LS, Banton MI, Bevan C, Cushman JR. Styrene respiratory tract toxicity and mouse lung tumors are mediated by CYP2F-generated metabolites. Regul. Toxicol. Pharmacol. 2002; 35:308–319. [PubMed: 12202046]



Figure 1.
P450 2E1 and P450 2F2 expressions in wild-type and *Cyp2e1*-null mouse liver and lung microsomes.



Figure 2.
P450 2E1 and P450 2F2 expressions in wild-type and *Cyp2f2*-null mouse liver and lung microsomes.



Scheme 1.

Table 1

4-Nitrophenol hydroxylation activity of *Cyp2e1*-null, *Cyp2f2*-null, and the corresponding wild-type mouse liver and lung microsomes. Mean ± SD, n = 3.

Mouse strain	Liver microsomes (nmol/min/mg protein)	Lung microsomes (nmol/min/mg protein)
129S1/SvImJ	2.50 ± 0.22	0.583 ± 0.008
Cyp2e1-null	1.33 ± 0.02*	0.436 ± 0.003*
C57BL/6J	2.84 ± 0.05	0.580 ± 0.029
Cyp2f2-null	2.41 ± 0.08*	0.081 ± 0.003*

* $p < 0.01$ compared to the wild-type mice.

Table 2

Velocity of the production of vinyl phenols (VPs) and styrene glycol (SG) in *Cyp2e1*-null and wild-type mouse liver and lung microsomal incubations with styrene (500 μM). Mean ± SD, n = 3.

	Liver microsomes				Lung microsomes			
	2-VP	**3-VP**	**4-VP**	**SG**	**2-VP**	**3-VP**	**4-VP**	**SG**
129S1/SvImJ	1.85 ± 0.15	0.089 ± 0.017	0.877 ± 0.026	2.09 ± 0.04	6.47 ± 0.96	0.155 ± 0.020	0.234 ± 0.047	1.31 ± 0.13
Cyp2e1-null	0.717 ± 0.145*	0.063 ± 0.011	0.278 ± 0.015*	1.17 ± 0.126*	4.35 ± 0.623†	0.163 ± 0.020	0.232 ± 0.015	1.37 ± 0.02

VPs: pmol/min/mg protein; SG: nmol/min/mg protein.

* $p < 0.01$,

† $p < 0.05$ compared to the wild-type mice.

Table 3

Velocity of the production of vinyl phenols (VPs) and styrene glycol (SG) in *Cyp2f2*-null and wild-type mouse liver and lung microsomal incubations with styrene (500 μM). Mean ± SD, n = 3.

	Liver microsomes				Lung microsomes			
	2-VP	**3-VP**	**4-VP**	**SG**	**2-VP**	**3-VP**	**4-VP**	**SG**
C57BL/6J	2.93 ± 0.15	0.370 ± 0.035	0.925 ± 0.082	2.44 ± 0.08	3.72 ± 0.54	0.181 ± 0.007	0.334 ± 0.019	1.13 ± 0.17
Cyp2f2-null	1.90 ± 0.58†	N.D.	N.D.	1.83 ± 0.02	N.D.	N.D.	N.D.	0.410 ± 0.007*

VPs: pmol/min/mg protein; SG: nmol/min/mg protein.

*$p < 0.01$,

†$p<0.05$ compared to the wild-type mice. N.D.: not detected.

Table 4

Kinetic parameters of styrene metabolism to styrene glycol in *Cyp2e1*-null, *Cyp2f2*-null, and the corresponding wild-type mouse liver and lung microsomes. Mean ± SD, n = 3.

Microsomes	Liver microsomes			Lung microsomes		
	K_m (μM)	V_{max} (nmol/min/mg)	V_{max}/K_m (L/min/g)	K_m (μM)	V_{max} (nmol/min/mg)	V_{max}/K_m (L/min/g)
129S1/SvImJ	7.96 ± 0.85	2.51 ± 0.28	0.32 ± 0.03	12.9 ± 1.3	2.03 ± 0.41	0.16 ± 0.03
Cyp2e1-null	6.20 ± 0.84	1.99 ± 0.32	0.32 ± 0.04	10.9 ± 1.5	1.88 ± 0.36	0.17 ± 0.02
C57BL/6J	25.7 ± 1.9	3.74 ± 0.47	0.14 ± 0.01	14.7 ± 3.0	3.34 ± 0.40	0.23 ± 0.02
Cyp2f2-null	13.5 ± 1.1*	2.64 ± 0.25†	0.20 ± 0.04	6.87 ± 2.6†	1.22 ± 0.25*	0.19 ± 0.04

*$p < 0.01$,

†$p < 0.05$ compared to the wild-type mice.

Table 5

Pulmonary toxicity of styrene in *Cyp2e1*-null, *Cyp2f2*-null, and the corresponding wild-type mice. Mean ± SD, n = 3.

	BALF cell counts (10^4/mL BALF)		BALF LDH activity (OD490)	
	Control	**Styrene**	**Control**	**Styrene**
129S1/SvImJ	2.7 ± 2.6	11.7 ± 3.7*	0.167 ± 0.069	1.297 ± 0.220*
Cyp2e1-null	1.2 ± 0.4	18.6 ± 9.6*	0.161 ± 0.072	0.757 ± 0.094*
C57BL/6J	2.8 ± 2.5	18.9 ± 6.8*	0.294 ± 0.063	0.944 ± 0.338*
Cyp2f2-null	3.1 ± 1.1	3.4 ± 1.3	0.152 ± 0.031	0.145 ± 0.040

* $p < 0.01$ compared to control.